Early pancreatic volume reduction on CT predicts relapse in patients with type 1 autoimmune pancreatitis treated with steroids by unknown
RESEARCH Open Access
Early pancreatic volume reduction on CT
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Abstract
Background: Type 1 autoimmune pancreatitis (AIP) is clinically characterized by a response to steroid therapy.
Despite having a favorable prognosis, AIP has a high relapse rate and factors predicting relapse in AIP patients
treated with steroids have not yet been established.
Methods: A retrospective chart review was conducted of 32 newly diagnosed type 1 AIP patients who had
undergone enhanced computed tomography (CT) pre- and post-steroid therapy.
Results: Ten patients experienced relapse. Pancreatic volume was reduced significantly in all patients (pre-treatment
volume, 88.5 ± 32.9 cm3 vs. post-treatment volume, 45.4 ± 21.1 cm3; P < 0.001), although the pre-treatment pancreatic
volume did not differ between the relapse and non-relapse groups (92.6 ± 10.5 cm3 vs. 86.6 ± 7.1 cm3, P = 0.401).
However, the post-treatment pancreatic volume was significantly greater in the relapse group than that in the non-
relapse group (56.9 ± 6.3 cm3 vs. 40.2 ± 4.2 cm3, P = 0.008). Similarly, the percent reduction in pancreatic volume was
significantly smaller in the relapse group than that in the non-relapse group (36.6 ± 4.7 % vs. 52.1 ± 3.2 %, P = 0.002).
Multivariate analysis identified post-treatment pancreatic volume (HR, 1.04, 95 % CI: 1.01–1.08, P = 0.010) and percent
reduction in pancreatic volume (HR, 0.87, 95 % CI: 0.79–0.94, P < 0.001) as predictive factors for relapse of type 1 AIP. A
post-treatment pancreatic volume of 50 cm3 < (P = 0.009) and a percent reduction in the pancreatic volume of <35 %
(P = 0.004) had a significantly high relapse rate. These data suggest that early pancreatic volume changes after steroid
therapy may be a useful prognostic value, because type 1 AIP patients with a high post-treatment pancreatic volume
or low pancreatic volume reduction showed significant relapse.
Conclusions: Early pancreatic volume reduction on CT after steroid therapy indicates the therapeutic effects of
steroids, and a low decrease in the pancreatic volume may be associated with a limited response that predicts future
relapse in patients with type 1 AIP. Reduction of steroids in these cases must be observed carefully with consideration
of immunomodulator use.
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Background
Type 1 autoimmune pancreatitis (AIP) is associated with
the enlargement of the pancreatic parenchyma, abun-
dant lymphoplasmacytic infiltration and fibrosis, and fre-
quent elevations in the serum immunoglobulin (Ig)-G4
levels. Although the precise pathogenesis of AIP has not
yet been determined, AIP is clinically characterized by a
response to steroid therapy, and it has a favorable prog-
nosis [1–6]. The remission rate of steroid-treated AIP is
98 %, which is significantly higher than 74 % of patients
without steroid treatment [7]. However, many patients
will experience disease relapse in type 1 AIP, and the re-
lapse rate for this type is 15–64 %, according to various
studies [7–10]. For most patients in previous reports, re-
lapses occurred after steroid discontinuation [7, 11].
Kamisawa et al. reported that continued maintenance
treatment with low-dose prednisolone for 6 months to
3 years is also recommended to prevent relapse in type 1
AIP [7]. Patients who resumed steroid treatment contin-
ued to respond favorably with a high remission rate. In
addition, some patients with relapse were treated with
an immunomodulator [9, 11]. Although there is general
agreement that long-term steroid therapy is the ideal ini-
tial treatment for preventing disease relapse, the inci-
dence of steroid-related side effects is a major concern.
If predictive factors of relapse or non-relapse in patients
with type 1 AIP exist, some patients may not require
long-term steroid maintenance therapy, and the inci-
dence of treatment-related side effects may decrease.
However, factors that may predict relapse have not yet
been established. In this context, the Ehime Pancreato-
Cholangiology (EPOCH) Study Group conducted a
retrospective study to identify the predictive factors of
relapse in patients with type 1 AIP by focusing on the
volume changes in the pancreas.
Methods
Patients
This study included 41 consecutive cases of type 1 AIP
according to the clinical diagnostic criteria proposed by
the Japan Pancreas Society [12] or the International
Consensus of Diagnostic Criteria [13] at six gastroenter-
ology clinics in Ehime (EPOCH Study Group), Japan,
from January 2006 to March 2015. Patients who were on
steroid therapy before the final diagnosis (N = 2), who
were not given steroid therapy (N = 3), and who did not
undergo post-treatment computed tomography (CT)
after steroid therapy (N = 4) were excluded. Finally, this
study included 32 newly diagnosed type 1 AIP patients
who underwent enhanced CT pre- and post-treatment.
In 23 patients (71.9 %), an accompanying pancreatic
malignancy was pathologically excluded by an endo-
scopic ultrasonography-guided fine needle aspiration
biopsy (N = 22) or by surgical resection (N = 1). The
median length of follow-up was 36 months (range,
3–107 months). Pre- and post-treatment data collection
included demographics (i.e., age and sex), complications
(e.g., jaundice and diabetes), markers associated with AIP
(i.e., IgG and IgG4), extra-pancreatic lesions detected on
CT, and extension of biliary stricture determined by mag-
netic resonance cholangiopancreatography or endoscopic
retrograde cholangiopancreatography (i.e., intrapancreatic,
extrapancreatic, and intrahepatic).
CT interval and methods of CT scan measurements
We measured the volumes of the pancreas as shown on
enhanced CT obtained before and within 6 months (me-
dian, 1.6 months) after steroid therapy. Early-phase
contrast-enhanced CT was used to measure the pancre-
atic volume, and the slice thickness was as follows:
5 mm (N = 29), 7 mm (N = 2), and 10 mm (N = 1). The
Synapse® Imaging System (Fuji Film) was used to meas-
ure the pancreatic volume, which was calculated by
summing the manually contoured area of the pancreatic
outline of each CT slice. The splenic volume was mea-
sured by using the same methods as those for pancreatic
volumetry.
Steroid therapy and disease relapse
The initial daily oral prednisolone dose was determined
by body weight (0.6 mg/kg per day), and it was 30 mg/
day in 27 patients (84 %). This dosage was administered
for about 2 weeks and then was tapered gradually until a
daily dose of 5–10 mg was reached, as per each physi-
cian’s decision. Maintenance steroid therapy was given
to all patients, and steroid therapy was discontinued in 4
patients (range, 9–12 months). The median length of
steroid therapy was 34 months. The relapsed group was
defined as follows: reappearance of the symptoms with
reappearance of pancreatic and/or extra-pancreatic ab-
normalities on imaging studies regardless of the serum
IgG or IgG4 levels [7].
Statistical analysis
The data were analyzed using JMP 9.0 (SAS Institute).
Differences and correlations in the pancreatic volume
before and after steroid therapy were compared using
the Wilcoxon signed-rank test. Receiver operating char-
acteristic (ROC) curves were generated, and the cutoff
was determined as the point in the ROC curve that max-
imized the value of sensitivity plus specificity. Cox pro-
portional hazards regression was used to perform
univariate and multivariate analyses of the predictors of
disease relapse. Relapse-free survival rates were calcu-
lated using the Kaplan-Meier method. P-values <0.05
were considered significant.
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Results
Clinical profiles
As shown in Table 1, a total of 32 newly diagnosed type
1 AIP patients were enrolled. Twenty-six patients
(81.3 %) were male, and the median age was 63 years
(range, 32–89 years). Patients presented with obstructive
jaundice (N = 13), abdominal pain or discomfort (N =
13), worsening of diabetes (N = 2), and abnormal abdom-
inal imaging (N = 4). Twenty-three patients (71.9 %) had
diffuse pancreatic swelling and 13 (40.6 %) had jaundice.
Patients had the following complications: bile duct stric-
ture (N = 26, 81.3 %), all were intrapancreatic but one
was intrahepatic; retroperitoneal fibrosis (N = 3, 9.4 %);
and sialadenitis (N = 2, 6.3 %). Twenty patients (62.5 %)
had diabetes: 12 patients preceded the diagnosis of AIP,
and 8 patients were diagnosed simultaneously with the
diagnosis of AIP. Relapse was observed in 10 patients
(31.3 %, relapsed group), with a median duration of
5.0 months (range, 2.1–47.2 months). The reasons for
relapse were as follows: symptoms and laboratory data
suggestive of bacterial cholangitis with an intrapancrea-
tic bile duct stricture (N = 6), acute pancreatitis (N = 3),
and swelling of the pancreas and the emergence of retro-
peritoneal fibrosis (N = 1) (Table 1). The relapse rate in
patients on maintenance therapy was significantly lower
than that in those who discontinued maintenance therapy
(23 % [7/30 patients] vs. 75 % [3/4 patients]; P = 0.033).
Surgeries were performed in 2 patients during the obser-
vation period. Pancreatic cancer was suspected in one;
however, this was not confirmed, and the other patient
had intractable bacterial cholangitis. Finally, all patients
survived, except one who died due to a cerebrovascular
disease.
Pancreatic volume change and a comparison of the
clinical profiles of the relapse and non-relapse groups
after steroid therapy
In all patients, the pancreatic volume on CT was reduced
significantly by steroid therapy (pre-treatment volume,
88.5 ± 32.9 cm3 vs. post-treatment volume, 45.4 ±
21.1 cm3; P < 0.001), with an average reduction of 47.3 ±
16.5 % (Fig. 1). When the relapse and non-relapse groups
were compared, the pancreatic volume did not differ be-
tween the two pre-treatment groups (92.6 ± 10.5 cm3 vs.
86.6 ± 7.1 cm3, P = 0.401). However, the post-treatment
pancreatic volume in the relapse group was significantly
higher than that in the non-relapse group (56.9 ± 6.3 cm3
vs. 40.2 ± 4.2 cm3; P = 0.008). Similarly, the percent reduc-
tion in the pancreatic volume was significantly smaller in
the relapse group than in the non-relapse group (36.6 ±
4.7 % vs. 52.1 ± 3.2 %, P = 0.002). Abdominal CT showed
favorable and unfavorable responses to steroid therapy in
patients with AIP (Fig. 2). The volume of the spleen on
CT was also measured, and it was slightly reduced by
steroid therapy (pre-treatment splenic volume, 134.7 ±
58.7 cm3 vs. post-treatment splenic volume, 116.1 ±
51.4 cm3, P < 0.001). However, when the relapse and non-
relapse groups were compared, the volume of the spleen
did not differ between the two pre-treatment groups.
In univariate analysis, variables other than the post-
treatment pancreatic volume and percent reduction in
the pancreatic volume failed to show an association
with relapse (Table 2, Fig. 3). Multivariate analysis used
two models and included the post-treatment pancreatic
volume (only in Model 1), percent reduction in the pancre-
atic volume (only in Model 2), diffuse pancreatic swelling,
bile duct stricture, and serum IgG4. Finally, the post-
treatment pancreatic volume (HR = 1.04, 95 % CI: 1.01–
1.08, P = 0.010) and percent reduction in the pancreatic
volume (HR = 0.87, 95 % CI: 0.79–0.94, P < 0.001) were
identified as a predictive factor for relapse in AIP (Table 3).
However, diffuse pancreatic swelling, bile duct stricture,
and serum IgG4 were not identified as predictive factors.
Predictive factors of relapse
In the ROC curve analysis, the optimal cut-off value of the
post-treatment pancreatic volume and the percent reduc-
tion in the pancreatic volume for relapse were determined
(Fig. 4, Table 4). A post-treatment pancreatic volume
50 cm3 < (area under the curve [AUC]: 0.72, sensitivity:
70 %, specificity: 81.8 %, P = 0.039) was associated with a
significantly high relapse rate in 6 of 10 cases. A percent
reduction in the pancreatic volume <35 % (AUC: 0.77,
sensitivity: 60 %, specificity: 81.8 %, P = 0.009) was also as-
sociated with a significantly high relapse rate in 6 of 9
cases. Furthermore, a post-treatment pancreatic volume
50 cm3 < or a percent reduction in the pancreatic volume
<35 % was associated with a significantly high relapse rate
Table 1 Clinical findings with type 1 autoimmune pancreatitis
Type 1 AIP (N = 32)
Age (years old) 63 (32–89)
Gender (male/female) 26 / 6
Imaging of pancreatic parenchyma
Diffuse swelling 23 (71.9 %)
Elevated serum IgG4 level (≧135 mg/dl) 25 (78.1 %)
Obstructive Jaundice 13 (40.6 %)
Bile duct stricture
Intrapancreatic 25 (78.1 %)
Extrapancreatic 0
Intrahepatic 1 (3.1 %)
Retroperitoneal fibrosis 3 (9.4 %)
Sialadenitis 2 (6.3 %)
Diabetes 20 (62.5 %)
Relapse of after steroid therapy 10 (31.2 %)
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Fig. 1 Comparison of the pancreatic volume change after steroid therapy. *1 < 0.001 by Wilcoxon signed-rank test. aPercent Reduction in
the Pancreatic Volume = 100 % - (pancreatic volume after steroid therapy/pancreatic volume before steroid therapy) × 100 %
Fig. 2 Abdominal computed tomography showing the pancreas in patients with autoimmune pancreatitis. The post-treatment pancreatic
volume was 30.3 cm3, and the percent reduction in the pancreatic volume was 68.2 % in a patient who showed a favorable response
without relapse before steroid therapy (a) and 2 weeks after starting steroid therapy (b). The pancreatic volume was not reduced in a
patient who showed an unfavorable response with relapse. The post-treatment pancreatic volume was 51.6 cm3, and the percent
reduction in the pancreatic volume was 42.3 % before steroid therapy (c) and after 2 months starting steroid therapy (d); at 47 months
during relapse, dilatation of the biliary tree (e) was observed
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(P = 0.002) in 9 of 16 cases. On the other hand, a post-
treatment pancreatic volume ≤50 cm3 and a percent re-
duction in the pancreatic volume 35 % ≤ had significantly
lower relapse rate, with a relapse in only 1/16 case.
Discussion
The histologic pattern of type 1 AIP is called lympho-
plasmacytic sclerosing pancreatitis, which is character-
ized by a periductal lymphoplasmacytic infiltrate,
storiform fibrosis, and obliterative venulitis [3, 4]. In our
study, the pancreatic volume on CT significantly reduced
by steroid therapy in all patients. However, when the re-
lapse and non-relapse groups were compared, the
change in pancreatic volume after steroid therapy was
significantly different. These findings may suggest that
the pancreatic volume change after steroid therapy re-
flects the histological findings in the pancreas. Accord-
ing to the histological findings previously reported, the
pancreatic parenchyma was replaced by massive or ex-
tensive interlobular fibrosis with lymphoplasmacytic in-
filtrates to varying degrees in advanced stages of type 1
AIP [14]. However, the pancreatic volumetric blood flow
of perfusion CT was attenuated in AIP, which improved
after steroid treatment [15]. The pancreatic volumetric
blood flow after steroid treatment may reflect the histo-
logical disease stage of type 1 AIP. Ko et al. reported that
the number of IgG4-positive plasma cells in pancreatic
tissue was decreased by steroid treatment, indicating a
reduction in inflammation [16]. Nevertheless, changes in
the histopathology after steroid treatment for AIP are
still unclear. Matsubayashi et al. reported a reduction in
the splenic volume by steroid therapy in cases with AIP
[17]. In our study, although the volume of the spleen








Age (years old) 61.6 ± 3.6 60.5 ± 2.4 0.799




IgG (mg/dl) 2020 ± 298 1877 ± 205 0.398
IgG4 (mg/dl) 525 ± 124 368 ± 84 0.483
Obstructive jaundice 4 9 0.560
Bile duct stricturea 8 17 0.795
Extra-pancreatic lesionsb 2 4 0.988
Diabetes 5 15 0.268
Pre-treatment pancreatic
volume (cm3)
92.6 ± 10.5 86.6 ± 7.1 0.401
Post-treatment pancreatic
volume (cm3)
56.9 ± 6.3 40.2 ± 4.2 0.008*
Percent reduction of pancreatic
volume (%)
36.6 ± 4.7 52.1 ± 3.2 0.002*
Pre-treatment splenic
volume (cm3)
133.9 ± 18.9 135.0 ± 12.7 0.959
Post-treatment splenic
volume (cm3)
116.5 ± 16.5 116.0 ± 11.1 0.836
Percent reduction of splenic
volume (%)
13.5 ± 6.3 12.3 ± 4.2 0.616
a Intrapancreatic bile duct stricture, except extrapancreatic and intrahepatic
bile duct stricture
b Intrahepatic bile duct stricture, retroperitoneal fibrosis, and sialadenitis
* < 0.05 by Cox proportional hazards regression analysis
Fig. 3 Comparison of pancreatic volume change in patients with or without relapse. *1 < 0.008, *2 < 0.002 by Cox proportional hazards regression.
aPercent Reduction in the Pancreatic Volume = 100 % - (pancreatic volume after steroid therapy/pancreatic volume before steroid therapy) × 100 %
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was reduced by steroid therapy, it did not differ between
the relapse and non-relapse groups.
In an analysis of 463 patients with AIP among 15 insti-
tutes in eight countries, Kamisawa et al. reported that the
relapse rate in patients treated with steroid ranged 15–
64 % [10]. The relapse rates in Western countries were
higher than those in Asian countries (United States, 64 %
vs. Japan, 15 %). The difference in the relapse rate was pre-
sumably due to the period from administration to cessa-
tion of steroid therapy (United States, 3 months vs. Japan,
1–2 years). Indeed, the majority of relapse episodes oc-
curred in steroid-treated subjects following steroid discon-
tinuation compared to those in whom the steroid dose
was being tapered or were on steroid maintenance therapy
[7, 11]. Continued maintenance treatment with low-dose
prednisolone for 6 months to 3 years is also recommended
to prevent relapse [7]. Although there is general agree-
ment that long-term steroid therapy is the ideal initial
treatment for preventing disease relapse, the incidence of
steroid-related side effects is a major concern. Shimizu et
al. reported that the cumulative dose of corticosteroids
was significantly higher in patients with serious side ef-
fects than in those without [18]. In our cases, maintenance
steroid therapy was given to all patients, and steroid ther-
apy was discontinued in only 4 patients. Some relapsed
patients are treated with an immunomodulator such as
azathioprine [9, 11], and these steroid-sparing approaches
Table 3 Results of multivariate analysis for disease relapse in
patients with AIP
HR 95 % CI P value
Model 1
Post-treatment pancreatic volume 1.04 1.01–1.08 0.010
Model 2
Percent reduction in the pancreatic volume 0.87 0.79–0.94 <0.001
Data are based on Cox proportional hazards regression
Model 1: post-treatment pancreatic volume, diffuse pancreatic swelling, bile
duct stricture (intrapancreatic bile duct stricture, except extrapancreatic and
intrahepatic bile duct stricture), and serum IgG4
Model 2: percent reduction in the pancreatic volume, diffuse pancreatic
swelling, bile duct stricture (intrapancreatic bile duct stricture, except
extrapancreatic and intrahepatic bile duct stricture), and serum IgG4
Fig. 4 Relapse-free survival rates after steroid therapy. a by post-treatment pancreatic volume (cm3); b by percent reduction in the pancreatic
volume (%); c by post-treatment pancreatic volume (cm3) and percent reduction of pancreatic volume (%). Log-rank test p values are reported
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are attractive for preventing complications from long-
term steroid exposure [19–22].
There are some reports regarding the relapse factors in
AIP. Diffuse pancreatic swelling was a predictive factor of
relapse [11]. The relapse rate of AIP was higher in patients
with IgG4-related sclerosing cholangitis (SC) than in those
without IgG4-related SC (56.1 % vs. 25.7 %, respectively)
[11]. IgG4 seropositivity and jaundice are at a higher risk
of relapse, and IgG4 seronegativity have a high likelihood
of spontaneous remission [23]. Diffuse pancreatic swelling
and proximal biliary involvement are predictive of relapse
in type 1 AIP [8], whereas distal biliary involvement was
not predictive in cases of type 1 AIP [11]. Additionally,
positive staining of the duodenal papilla for IgG4 and a
swollen duodenal papilla had a favorable response to ster-
oid therapy [24]. However, factors that may predict relapse
have not been well defined, and some are still controver-
sial. Indeed, our study failed to show that the diffuse type
IgG4 seropositivity and jaundice were predictive factors of
relapse. Moreover, these factors are examined at the time
of diagnosis, and they are not intended to reflect the
course of treatment.
Over the course of treatment, our findings suggest that
early pancreatic volume changes after steroid therapy
may be a useful prognostic value, because patients with
AIP with a high post-treatment pancreatic volume
(50 cm3<) or low pancreatic volume reduction (<35 %)
showed a significant relapse. Reduction of steroids in
these cases must be observed carefully with consider-
ation of immunomodulator use, such as azathioprine.
On the other hand, patients who had a post-treatment
pancreatic volume ≤50 cm3 and a percent reduction in
the pancreatic volume 35 % ≤ had a significantly lower
relapse rate. In other words, a low post-treatment pan-
creatic volume and a high pancreatic volume reduction
may predict non-relapse in patients with AIP. Therefore,
these measures may be useful for selecting suitable can-
didates for steroid discontinuation to prevent treatment-
related side effects. However, Masuda et al. reported that
AIP patients with pancreatic atrophy after steroid ther-
apy have a high incidence of diabetes mellitus [25]. Al-
though our cases did not fit into the definition of
pancreatic atrophy proposed by Hirano et al. [26] at the
time of CT measurement after steroid therapy, some
cases might further reduce their pancreatic volume with
a longer period of steroid therapy and develop diabetes.
These reports also support the abovementioned idea to
discontinue steroid in selected patients.
As is common for studies with retrospective designs,
our study has the following limitations: small sample
size; not all patients underwent a histological examin-
ation; and the steroid treatment regimen, period of ster-
oid therapy, and timing of CT were not uniform. To
overcome these limitations, further long-term prospect-
ive studies in a larger cohort are needed to examine the
relationship between the pancreas volume reduction and
relapse in AIP treated with steroids. Nevertheless, we be-
lieve that our findings currently present one of the best
factors for predicting relapse in patients with AIP.
Conclusions
Early pancreatic volume reduction on CT after steroid
therapy reflects therapeutic effects of steroid and pre-
dicts future relapse in patients with type 1 AIP. Reduc-
tion of steroids in these cases must be observed carefully
with consideration of immunomodulator use.
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